Gilead Sciences (GILD) 105.89 $GILD
Final Glance: Biotechnology companies
AP - Tue Sep 09, 7:15PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
AstraZeneca Presents Unfavorable Benralizumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 5:35PM CDT
AstraZeneca (AZN) announced that data on its respiratory disease candidate, benralizumab, was published in The Lancet Respiratory Medicine.
Glaxo (GSK) Updates on Asthma Candidate Mepolizumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 5:20PM CDT
GlaxoSmithKline announced positive data from two pivotal phase III studies on its asthma candidate, mepolizumab.
Pluristem & United Therapeutics Progress with Phase I Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 3:50PM CDT
Pluristem Therapeutics Inc. (PSTI) announced today that its licensee, United Therapeutics Corporation (UTHR), completed dosing of the first of the three cohorts of patients in a phase I study.
Hospira Down on Legal Blow; Court Allows Generic Precedex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 3:45PM CDT
Hosipra (HSP) suffered a setback with the court allowing the sale of generic Precedex.
Bayer Presents Positive Long-Term Results on Adempas - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 3:25PM CDT
Bayer (BAYRY) announced positive results from long-term extension studies on Adempas.
Midday Glance: Biotechnology companies
AP - Tue Sep 09, 12:23PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Sep 09, 9:44AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Critical Alerts For Gilead Sciences, Incyte Corp., Infinera Corporation, Ford and Pixelworks Released By InvestorsObserver
PR Newswire - Tue Sep 09, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GILD, INCY, INFN, F and PXLW.
Global Infectious Disease Treatment Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Gilead Sciences, GSK, J&J Merck & Pfizer
M2 - Tue Sep 09, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5tdjb4/global_infectious) has announced the addition of the "Global Infectious Disease Treatment Market 2014-2018" report to their offering. The analysts forecast the Global Infectious Disease Treatment market to grow at a CAGR of 3.43% over the period 2013-2018. Infectious diseases can be caused by various pathogenic microorganisms such as bacteria, fungi, parasites, or viruses. These diseases can be transmitted from one individual to another through either direct contact or indirect contact. Anti-infective drugs are used to kill (cidal) or stop the growth (static) of infectious agents. Based on the target organism, anti-infective drugs can be categorized into antibacterial, antiviral, antifungal, and antiparasitic. One of the emerging trends in this market is the emergence of Interferon-free regimens. Various all-oral, IFN-free regimens are under development and are expected to attain higher sustained virologic response and cause fewer side effects than the currently approved therapies. According to the report, the launch of Direct-acting Antivirals is one of the major drivers for the Global Infectious Disease Treatment market. DAAs are administered in combination with other antiviral drugs such as ribavirin and PEG-IFN and increase the efficacy of treatment and decrease the duration of therapy and this leads to increased preference for this treatment among patients. Further, the report states that a generic erosion of marketed drugs is one of the major challenges faced by the market. A loss of patent protection and market exclusivity generally triggers the entry of low-cost alternatives for drugs, which, in turn, decreases the sales of innovator-approved drugs. To calculate the market size, the report considers the revenue generated through the sales of various drugs administered to treat various infectious diseases caused by bacteria, virus, fungi, and parasites, which include: - Antibacterial drugs (beta-lactams, macrolides, aminoglycosides, phenicols, quinolones, sulfonamides, tetracyclines, and other antibacterials) - Antiviral drugs (HIV, hepatitis C, hepatitis B, and other antivirals) - Antifungal drugs (azoles, pyrimidines, echinodians, polyenes, allylamines, and other antifungal drugs) - Antiparasitic drugs Key Vendors - F. Hoffmann-La Roche - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck - Pfizer For more information visit http://www.researchandmarkets.com/research/5t...infectious
Keryx Falls after Ferric Citrate's Approval with Warnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 5:05PM CDT
The FDA has approved Keryx's (KERX) ferric citrate to control serum phosphorus levels in patients suffering from CKD on dialysis.
OncoMed's Shares Gain on Lifting of Partial Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 5:00PM CDT
OncoMed Pharmaceuticals' (OMED) shares were up 5.7% with the FDA lifting the partial clinical hold on ipafricept for ovarian cancer, pancreatic cancer and liver cancer.
Prana Biotechnology Up on Orphan Drug Status for PBT2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:35PM CDT
The FDA has granted orphan drug designation to Prana Biotechnology's Huntington disease candidate, PBT2.
Novartis (NVS) Presents Positive Data on Ultibro Breezhaler - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:05PM CDT
Novartis (NVS) presented encouraging data on Ultibro Breezhaler from the LANTERN study at the European Respiratory Society (ERS) International Congress in Germany.
Bayer/Regeneron Looking for Eylea Label Expansion in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 3:45PM CDT
Bayer submitted an MAA for Eylea in Japan for the treatment of patients suffering from macular edema secondary to BRVO.
Bristol-Myers Sues Merck of Patent Infringement on Keytruda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 3:30PM CDT
Bristol-Myers (BMY) filed a patent infringement case against Merck (MRK).
Gilead Down on Likely Sovaldi Generic Deal in Poor Nations - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 2:39PM CDT
Gilead (GILD) is in talks with generic players on Sovaldi.
Pharmacyclics Price Target Cut On Higher Spending
at Investor's Business Daily - Mon Sep 08, 12:02PM CDT
Biotech Pharmacyclics (PCYC) got a price-target cut from Nomura on Monday, but the investment bank maintained a buy rating on Pharmacyclics stock, saying the company's competitive position remains strong. Pharmacyclics stock was flat in midday...
Atrial Fibrillation - Pipeline Review Report, H2 2014 - 15 Companies & 27 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xr5nbq/atrial) has announced the addition of the "Atrial Fibrillation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - AstraZeneca PLC - Isis Pharmaceuticals, Inc. - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Nissan Chemical Industries, Ltd. - Laboratoires Pierre Fabre SA - Cardiome Pharma Corp - Xention Limited - HUYA Bioscience International, LLC - Milestone Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Serodus ASA - Nyken BV - Armetheon, Inc. Drug Profiles - edoxaban tosylate - tecarfarin - vernakalant hydrochloride - bucindolol hydrochloride - vernakalant hydrochloride - ranolazine ER - XEN-D0103 - HBI-3000 - ISIS-CRPRx - (ranolazine dronedarone) - vanoxerine - F-373280 - BMS-919373 - XEN-D0101 - OPC-108459 - budiodarone - Small Molecule to Inhibit IKACh for Atrial Fibrillation - MSP-2017 - NYK-1112 - SER-102 - XEN-R0702 - GsMTx-4 - NIP-151 - Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug For Atrial Fibrillation - Small Molecule To Activate Heat Shock Protein 70 (Hsp70) For Post-Operative Atrial Fibrillation - Small Molecules to Inhibit Voltage Gated Sodium Channel for Atrial Fibrillation For more information visit http://www.researchandmarkets.com/research/xr5nbq/atrial
Final Glance: Biotechnology companies
AP - Tue Sep 09, 7:15PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
AstraZeneca Presents Unfavorable Benralizumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 5:35PM CDT
AstraZeneca (AZN) announced that data on its respiratory disease candidate, benralizumab, was published in The Lancet Respiratory Medicine.
Glaxo (GSK) Updates on Asthma Candidate Mepolizumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 5:20PM CDT
GlaxoSmithKline announced positive data from two pivotal phase III studies on its asthma candidate, mepolizumab.
Pluristem & United Therapeutics Progress with Phase I Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 3:50PM CDT
Pluristem Therapeutics Inc. (PSTI) announced today that its licensee, United Therapeutics Corporation (UTHR), completed dosing of the first of the three cohorts of patients in a phase I study.
Hospira Down on Legal Blow; Court Allows Generic Precedex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 3:45PM CDT
Hosipra (HSP) suffered a setback with the court allowing the sale of generic Precedex.
Bayer Presents Positive Long-Term Results on Adempas - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 3:25PM CDT
Bayer (BAYRY) announced positive results from long-term extension studies on Adempas.
Midday Glance: Biotechnology companies
AP - Tue Sep 09, 12:23PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Sep 09, 9:44AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Critical Alerts For Gilead Sciences, Incyte Corp., Infinera Corporation, Ford and Pixelworks Released By InvestorsObserver
PR Newswire - Tue Sep 09, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GILD, INCY, INFN, F and PXLW.
Global Infectious Disease Treatment Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Gilead Sciences, GSK, J&J Merck & Pfizer
M2 - Tue Sep 09, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5tdjb4/global_infectious) has announced the addition of the "Global Infectious Disease Treatment Market 2014-2018" report to their offering. The analysts forecast the Global Infectious Disease Treatment market to grow at a CAGR of 3.43% over the period 2013-2018. Infectious diseases can be caused by various pathogenic microorganisms such as bacteria, fungi, parasites, or viruses. These diseases can be transmitted from one individual to another through either direct contact or indirect contact. Anti-infective drugs are used to kill (cidal) or stop the growth (static) of infectious agents. Based on the target organism, anti-infective drugs can be categorized into antibacterial, antiviral, antifungal, and antiparasitic. One of the emerging trends in this market is the emergence of Interferon-free regimens. Various all-oral, IFN-free regimens are under development and are expected to attain higher sustained virologic response and cause fewer side effects than the currently approved therapies. According to the report, the launch of Direct-acting Antivirals is one of the major drivers for the Global Infectious Disease Treatment market. DAAs are administered in combination with other antiviral drugs such as ribavirin and PEG-IFN and increase the efficacy of treatment and decrease the duration of therapy and this leads to increased preference for this treatment among patients. Further, the report states that a generic erosion of marketed drugs is one of the major challenges faced by the market. A loss of patent protection and market exclusivity generally triggers the entry of low-cost alternatives for drugs, which, in turn, decreases the sales of innovator-approved drugs. To calculate the market size, the report considers the revenue generated through the sales of various drugs administered to treat various infectious diseases caused by bacteria, virus, fungi, and parasites, which include: - Antibacterial drugs (beta-lactams, macrolides, aminoglycosides, phenicols, quinolones, sulfonamides, tetracyclines, and other antibacterials) - Antiviral drugs (HIV, hepatitis C, hepatitis B, and other antivirals) - Antifungal drugs (azoles, pyrimidines, echinodians, polyenes, allylamines, and other antifungal drugs) - Antiparasitic drugs Key Vendors - F. Hoffmann-La Roche - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck - Pfizer For more information visit http://www.researchandmarkets.com/research/5t...infectious
Keryx Falls after Ferric Citrate's Approval with Warnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 5:05PM CDT
The FDA has approved Keryx's (KERX) ferric citrate to control serum phosphorus levels in patients suffering from CKD on dialysis.
OncoMed's Shares Gain on Lifting of Partial Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 5:00PM CDT
OncoMed Pharmaceuticals' (OMED) shares were up 5.7% with the FDA lifting the partial clinical hold on ipafricept for ovarian cancer, pancreatic cancer and liver cancer.
Prana Biotechnology Up on Orphan Drug Status for PBT2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:35PM CDT
The FDA has granted orphan drug designation to Prana Biotechnology's Huntington disease candidate, PBT2.
Novartis (NVS) Presents Positive Data on Ultibro Breezhaler - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:05PM CDT
Novartis (NVS) presented encouraging data on Ultibro Breezhaler from the LANTERN study at the European Respiratory Society (ERS) International Congress in Germany.
Bayer/Regeneron Looking for Eylea Label Expansion in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 3:45PM CDT
Bayer submitted an MAA for Eylea in Japan for the treatment of patients suffering from macular edema secondary to BRVO.
Bristol-Myers Sues Merck of Patent Infringement on Keytruda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 3:30PM CDT
Bristol-Myers (BMY) filed a patent infringement case against Merck (MRK).
Gilead Down on Likely Sovaldi Generic Deal in Poor Nations - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 2:39PM CDT
Gilead (GILD) is in talks with generic players on Sovaldi.
Pharmacyclics Price Target Cut On Higher Spending
at Investor's Business Daily - Mon Sep 08, 12:02PM CDT
Biotech Pharmacyclics (PCYC) got a price-target cut from Nomura on Monday, but the investment bank maintained a buy rating on Pharmacyclics stock, saying the company's competitive position remains strong. Pharmacyclics stock was flat in midday...
Atrial Fibrillation - Pipeline Review Report, H2 2014 - 15 Companies & 27 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xr5nbq/atrial) has announced the addition of the "Atrial Fibrillation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - AstraZeneca PLC - Isis Pharmaceuticals, Inc. - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Nissan Chemical Industries, Ltd. - Laboratoires Pierre Fabre SA - Cardiome Pharma Corp - Xention Limited - HUYA Bioscience International, LLC - Milestone Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Serodus ASA - Nyken BV - Armetheon, Inc. Drug Profiles - edoxaban tosylate - tecarfarin - vernakalant hydrochloride - bucindolol hydrochloride - vernakalant hydrochloride - ranolazine ER - XEN-D0103 - HBI-3000 - ISIS-CRPRx - (ranolazine dronedarone) - vanoxerine - F-373280 - BMS-919373 - XEN-D0101 - OPC-108459 - budiodarone - Small Molecule to Inhibit IKACh for Atrial Fibrillation - MSP-2017 - NYK-1112 - SER-102 - XEN-R0702 - GsMTx-4 - NIP-151 - Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug For Atrial Fibrillation - Small Molecule To Activate Heat Shock Protein 70 (Hsp70) For Post-Operative Atrial Fibrillation - Small Molecules to Inhibit Voltage Gated Sodium Channel for Atrial Fibrillation For more information visit http://www.researchandmarkets.com/research/xr5nbq/atrial
